Journal article
Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids
Scientific reports, Vol.4(1), pp.4645-4645
04/10/2014
DOI: 10.1038/srep04645
PMCID: PMC3982175
PMID: 24717973
Abstract
Inadequate immunomodulatory potency of mesenchymal stem cells (MSC) may limit their therapeutic efficacy. We report glucocorticoid steroids augment MSC expression and activity of indoleamine-2,3-dioxygenase (IDO), a primary mediator of MSC immunomodulatory function. This effect depends on signaling through the glucocorticoid receptor and is mediated through up-regulation of FOXO3. Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression following IFN-γ stimulation in multiple donors and was able to restore IDO expression in over-passaged MSCs. As IDO enhancement was most notable when cells were continuously exposed to budesonide, we engineered MSC with budesonide loaded PLGA microparticles. MSC efficiently internalized budesonide microparticles and exhibited 4-fold enhanced IDO activity compared to budesonide preconditioned and naïve MSC, resulting in a 2-fold improvement in suppression of stimulated peripheral blood mononuclear cells in an IDO-dependent manner. Thus, the augmentation of MSC immune modulation may abrogate challenges associated with inadequate potency and enhance their therapeutic efficacy.
Details
- Title: Subtitle
- Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids
- Creators
- James A Ankrum - 1] Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USARiddhi G Dastidar - Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USAJoon Faii Ong - Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USAOren Levy - Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USAJeffrey M Karp - 1] Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA
- Resource Type
- Journal article
- Publication Details
- Scientific reports, Vol.4(1), pp.4645-4645
- DOI
- 10.1038/srep04645
- PMID
- 24717973
- PMCID
- PMC3982175
- NLM abbreviation
- Sci Rep
- ISSN
- 2045-2322
- eISSN
- 2045-2322
- Publisher
- England
- Grant note
- R01 HL095722 / NHLBI NIH HHS HL095722, / NHLBI NIH HHS
- Language
- English
- Date published
- 04/10/2014
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering
- Record Identifier
- 9984001095702771
Metrics
27 Record Views